Efficacy and Safety of Atezolizumab in Chinese Patients With Advanced Thymic Carcinoma: A Multicenter, Single-Arm Phase 2 Study
In patients with advanced thymic carcinoma who had failed prior systemic therapy, atezolizumab was well-tolerated with a manageable toxicity profile and showed encouraging the antitumor activity, especially in patients with PD-L1-positive tumors.
Authors
- Shun Lü (ORCID: https://orcid.org/0000-0001-8833-7262)
- Dandan Hu (ORCID: https://orcid.org/0000-0002-3455-5253)
- Lunxu Liu (ORCID: https://orcid.org/0000-0003-3964-5378)
- Mo Chen (ORCID: https://orcid.org/0009-0006-7757-3191)
- Yi Zhou (ORCID: https://orcid.org/0000-0001-9616-7283)
- Chun Chen (ORCID: https://orcid.org/0000-0002-1369-6938)
- Rui Li (ORCID: https://orcid.org/0000-0002-7210-8358)
- Changli Wang (ORCID: https://orcid.org/0000-0003-3088-4604)
- Xuezhen Ma
- Yanjun Shi (ORCID: https://orcid.org/0009-0002-2096-6032)
- Zhenzhou Yang (ORCID: https://orcid.org/0000-0003-2368-0240)
- Xiufeng Hu
- Junwen M. Hu (ORCID: https://orcid.org/0000-0001-9571-9947)
- Jianxing He
Institutions
- Qingdao University (CN)
- Fujian Medical University (CN)
- Dalian Medical University (CN)
- Sichuan University (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Shanghai Chest Hospital (CN)
- Zhengzhou University (CN)
- West China Hospital of Sichuan University (CN)
- Second Affiliated Hospital of Chongqing Medical University (CN)
- First Affiliated Hospital of Guangzhou Medical University (CN)
- Affiliated Hospital of Qingdao University (CN)
- Sichuan Cancer Hospital (CN)
- Roche (China) (CN)
- Henan Cancer Hospital (CN)
- State Key Laboratory of Respiratory Disease (CN)
- Union Hospital (CN)
- Zhejiang University (CN)
- Chongqing Medical University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Clinical Lung Cancer
- Published
- 2025-01-29
- DOI
- https://doi.org/10.1016/j.cllc.2025.01.011
- Citations
- 1
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- F. Hoffmann-La Roche